hackint0sh/New-Dataset huggingface dataset:
The pathological prediction model and accurate risk assessment system of colorectal tubular adenoma were constructed by the pathological database. conditions: Colorectal Tubular Adenoma studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 30000 type: ESTIMATED measure: Clinical information such as demographic characteristics, clinical data, endoscopy and pathological images sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06322212 id: 23-001083 briefTitle: Type 2 Diabetes and Blood Brain Barrier Improvement overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-12 date: 2026-04 date: 2024-03-20 date: 2024-03-20 name: University of California, Los Angeles class: OTHER briefSummary: The majority of T2DM adults show thiamine (vitamin B1) deficiency which may contribute to impaired function. This study will examine patients with T2DM through brain MRI scans, cognition assessments, blood tests, and questionnaires. Our goal is to see if a thiamine treatment (taking vitamin B1 capsules) can improve function. Patients will be asked to come to UCLA two times three months apart and each visit will last about 2.5-3 hours. conditions: Type2diabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Compare BBB function, cognition, and mood in T2DM adults with and without Thiamine treatment. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Participants will be assigned a number to be used instead of their names with double-blind randomization until visits are complete and data is analyzed. whoMasked: PARTICIPANT count: 52 type: ESTIMATED name: Thiamine name: Placebo measure: Assess if BBB function has been repaired. measure: Analyze blood serum S100β levels. measure: Examine cognition in T2DM adults with thiamine treatment. measure: Cognition assessment in T2DM adults after thiamine treatment. measure: Examine depression in T2DM adults with thiamine treatment. measure: Assess anxiety in T2DM adults with thiamine treatment. sex: ALL minimumAge: 40 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UCLA city: Los Angeles state: California zip: 90095 country: United States lat: 34.05223 lon: -118.24368 typeAbbrev: Prot_ICF hasProtocol: True hasSap: False hasIcf: True label: Study Protocol and Informed Consent Form date: 2023-11-17 uploadDate: 2024-03-07T13:21 filename: Prot_ICF_000.pdf size: 309752 hasResults: False
nctId: NCT06322199 id: 2021-02504 (Project 3) briefTitle: Differences Between Suicide Attempters and Suicide Ideators. Influence of the Brief Therapy Attempted Suicide Short Intervention Program (ASSIP) on Neuropsychological Correlates and Psychological Process Factors - Project 3 acronym: NePsyAssip HT overallStatus: RECRUITING date: 2022-09-23 date: 2024-12-31 date: 2024-12-31 date: 2024-03-20 date: 2024-03-20 name: University of Bern class: OTHER briefSummary: The present study consists of 3 projects in total. It aims to investigate the (neuro-) psychological patterns from suicidal ideation to suicidal behavior as well as the feasibility and cost-effectiveness of ASSIP flex.
The overall aim of Project 3 is to evaluate the feasibility and cost-effectiveness of ASSIP flex over a 12-month follow-up period in terms of suicide reattempts and suicide correlates in a cohort who is attending ASSIP flex after a suicide attempt. conditions: Suicide, Attempted conditions: Suicidal Ideation conditions: Feasibility conditions: Cost-effectiveness conditions: Process Factors studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 60 type: ESTIMATED name: ASSIP (Attempted Suicide Short Intervention Program) flex measure: Suicidal ideation (Baseline, t0) measure: Suicidal ideation and suicidal behavior (Baseline, t0) measure: Suicidal ideation (Follow-up, t1) measure: Suicidal ideation and suicidal behavior (Follow-up, t1) measure: Suicidal ideation (Follow-up, t2) measure: Suicidal ideation and suicidal behavior (Follow-up, t2) measure: Treatment costs of treatments 1 measure: Sociodemographic data measure: Depressive symptoms measure: General sense of self-efficacy measure: Self-Management measure: Health Literacy measure: Loneliness measure: Therapeutic Alliance measure: Adherence and Competence sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre Hospitalier universitaire vaudois (CHUV) status: RECRUITING city: Lausanne country: Switzerland lat: 46.516 lon: 6.63282 facility: Center Neuchâtelois de Psychiatrie status: RECRUITING city: Neuchâtel country: Switzerland lat: 46.99179 lon: 6.931 facility: Psychiatric Hospital, University of Zurich (PUKZH) status: RECRUITING city: Zürich country: Switzerland lat: 47.36667 lon: 8.54999 facility: Sanatorium Kilchberg status: RECRUITING city: Zürich country: Switzerland lat: 47.36667 lon: 8.54999 hasResults: False
nctId: NCT06322186 id: STAYWARM-2 Trial briefTitle: Study to Actively Warm Trauma Patients-2 acronym: STAYWARM-2 overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-03 date: 2026-03 date: 2024-03-20 date: 2024-03-20 name: Sunnybrook Health Sciences Centre class: OTHER briefSummary: Massively bleeding trauma patients have higher odds of mortality, increased hospital length of stay, and increased need for transfusion if they become hypothermic. Hypothermia is independently associated with mortality in traumatically injured patients due to its negative physiologic effects on hemostasis, cardiorespiratory and renal function.
Current warming strategies increase the logistical difficulty of transferring patients (which is frequent during the initial hours of trauma care) or must be changed at frequent intervals. Prehospital, military, and intraoperative studies have suggested chemical warming blankets as a pragmatic strategy to manage hypothermia. A recent pilot study (manuscript under review) at our institution demonstrated the feasibility of using the Ready-Heat® (TechTrade LLC, Orlando, FL, USA) chemical heating blanket in the initial phases of hospital care in bleeding trauma patients requiring a mass hemorrhage protocol (MHP). These self-warming blankets provide warmth over 8 hours at up to 40 degrees Celsius, carrying the advantage of portability with no continuous electric power requirement. Furthermore, the Ready-Heat blanket may be more effective than current strategies for rewarming patients at high risk of developing hypothermia. STAYWARM-2 will be the first randomized controlled trial performed in-hospital to evaluate a self-warming blanket to address hypothermia in massively bleeding trauma patients within the initial hours of hospital arrival.
This study will help to determine the efficacy and feasibility of using chemical heating blankets for hypothermia in the early hours of hospital care. This has potential to reduce the overall workload of direct care clinicians, freeing them for other patient care duties. Additionally, the intervention may achieve enhanced thermoregulation compared to current strategies, improving patient care and comfort, and avoiding the clinical complications related to hypothermia. Findings from this preliminary study may provide data for a future grant to launch a larger randomized controlled trial in the prehospital/in-hospital trauma setting to optimize the care of patients at risk of developing hypothermia. conditions: Trauma Injury conditions: Hypothermia conditions: Massive Hemorrhage studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Eligible patients will be randomized 1:1 to receive either the experimental or control arm.
Experimental arm: 2 Ready-Heat 4-panel blankets Control arm: standard of care (use of warmed blankets and forced air warmed blanket \[FAWB\]) primaryPurpose: OTHER masking: SINGLE maskingDescription: Only the statistician will remain blinded during the final analysis. whoMasked: OUTCOMES_ASSESSOR count: 74 type: ESTIMATED name: Ready-Heat Chemical Heating Blankets name: Warmed blankets or FAWB measure: An increase of 1⁰C at eight hours from the time of blanket placement measure: Adherence to the 2 blankets application in the trauma bay in at least 80% of patients. measure: Adherence to body temperature measurements (in degrees Celsius) 80% of each of the phases of initial care up to 8 hours following admission. measure: Adherence to maintain the blankets applied on the patient in 80% of each of the phases of initial care up to 8 hours following admission. measure: Concurrent warming strategies measure: Blood product usage measure: Coagulation parameter 1: platelet count measure: Coagulation parameter 2: INR measure: Coagulation parameter 3: fibrinogen measure: Perfusion parameter 1: pH measure: Perfusion parameter 2: base deficit measure: Perfusion parameter 3: serum lactate measure: Hemoglobin level measure: Blanket placed directly on skin measure: Skin redness and/or burns sex: ALL minimumAge: 16 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-08-21 uploadDate: 2024-02-21T15:24 filename: Prot_SAP_000.pdf size: 1303584 hasResults: False
nctId: NCT06322173 id: 2022-13 briefTitle: Molecular Diagnostics of Bacterial Infections and Antibiotic Resistance in Blood Samples and Rectal Swabs Using Advanced NGS Sequencing Methods acronym: ARES_NGS overallStatus: RECRUITING date: 2022-06-28 date: 2024-12 date: 2024-12 date: 2024-03-20 date: 2024-03-20 name: IRCCS Sacro Cuore Don Calabria di Negrar class: OTHER briefSummary: This is an experimental study without drug and device, non-profit, on biological samples stored at the Tropica Biobank of the DITM. The aim of the project is to verify the performance of NGS-based assays, which can be used in the field of microbiology. The clinical evaluation investigations of NGS technology will be conducted on an adequate number of clinical blood samples and rectal swabs. The analyzes will be compared with the standard microbiology methods used in the DITM diagnostic routine. conditions: Resistance Bacterial studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 100 type: ESTIMATED name: NGS Analysis measure: Microorganism presence (positive/negative) measure: Microorganism identification measure: Identification of Gene mutations that convey resistance to antibiotics (resistant/susceptible) sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Sacro Cuore Don Calabria hospital status: RECRUITING city: Negrar state: Verona zip: 37024 country: Italy name: Elena Pomari role: CONTACT phone: +390456013111 email: elena.pomari@sacrocuore.it name: Elena Pomari role: PRINCIPAL_INVESTIGATOR name: Pierantonio Orza role: SUB_INVESTIGATOR name: Francesca Perandin role: SUB_INVESTIGATOR lat: 45.52918 lon: 10.93899 hasResults: False
nctId: NCT06322160 id: 5714 briefTitle: The Role of tHyroid cAncer Specific Patient Concerns iNventory (PCI-TC) in Enhancing Shared decisiOn Making acronym: HANSOM overallStatus: RECRUITING date: 2023-05-03 date: 2024-12-31 date: 2024-12-31 date: 2024-03-20 date: 2024-03-20 name: Royal Marsden NHS Foundation Trust class: OTHER name: ENTUK briefSummary: Multiple clinical equipoises exist for the management of thyroid cancers. Shared decision-making (SDM) process where patients are supported to consider options, to achieve informed preferences with their clinicians have been recommended to improve patients' satisfaction and their overall quality of life. However, SDM can be difficult to achieve in our standard clinical encounters due to clinician's lack of confidence and time limitation to elicit patient's concerns and preferences. PCI as a decision-making support tool has shown to enhances clinician's awareness of patient's needs and allows for a more effective communication while the consultation time is unaffected. The successful development, testing and implementation of a PCI-TC could improve patient satisfaction, clinical efficiency and ensure that unmet need is appropriately addressed. This study will support the development of PCI-TC to better understand the wide-ranging needs of our patients and to improve the SDM process in the thyroid cancer management pathway. conditions: Thyroid Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 32 type: ESTIMATED name: Interview measure: To explore patients' and clinicians' view and experience of the current decision-making process for low risk differentiated thyroid cancer measure: • To explore clinicians' and patients' user experience of thyroid cancer specific patient concerns inventory (PCI-TC) in thyroid cancer outpatient clinics. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Guys & St Thomas status: RECRUITING city: London country: United Kingdom name: Aleix Mr Rovira, PhD role: CONTACT lat: 51.50853 lon: -0.12574 facility: UCLH status: RECRUITING city: London country: United Kingdom name: Francis Mr Vaz, FRCS role: CONTACT lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06322147 id: KYLL-202304-31 briefTitle: Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer overallStatus: RECRUITING date: 2023-06-01 date: 2024-12-30 date: 2025-12-30 date: 2024-03-20 date: 2024-03-20 name: Qilu Hospital of Shandong University class: OTHER briefSummary: This study was designed as multi-center, ambispective observational trial to evaluate the efficacy and safety of addition of cetuximab to doublet or triplet chemotherapy as conversion therapy in right-sided BRAF/RAS wild-type CRLM with curative intent. The primary endpoint was radical resection rate (R0). The secondary endpoint was response rate, rate of NED, depth of remission, early tumor shrinkage, progression free survival and safety. conditions: Colon Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 50 type: ESTIMATED name: Doublet or triplet chemotherapy combined with cetuximab measure: R0 resection rate measure: Objective response rate measure: Reported adverse events measure: Progression free survival measure: no evidence of disease measure: depth of response measure: Early Tumor Shrinkage sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Qilu hospital of Shandong University status: RECRUITING city: Jinan state: Shandong zip: 250012 country: China name: xiangling Wang, Dr. role: CONTACT phone: 8653182169841 email: xlwang71@163.com name: Jing Hao role: PRINCIPAL_INVESTIGATOR lat: 36.66833 lon: 116.99722 hasResults: False
nctId: NCT06322134 id: DROWN_SAR briefTitle: Drowning Incidents Treated by the Danish SAR Helicopters acronym: DROWN_SAR overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-01 date: 2024-12-31 date: 2024-12-31 date: 2024-03-20 date: 2024-03-25 name: Prehospital Center, Region Zealand class: OTHER briefSummary: Improving oxygenation and ventilation in drowning patients early in the field is critical and may be lifesaving. This may be achieved by helicopter emergency medical services (HEMS) such as the Danish Air Ambulance, or the Royal Danish Air Force's Search And Rescue (SAR) helicopters. The SAR operates in all weather conditions and is equipped with a hoist system, able to hoist patients from the sea or small ships without helipads. This study aimed to estimate the incidence of drowning missions attended by the Royal Danish Air Force's SAR helicopter and describe patient characteristics and prehospital interventions. conditions: Drowning conditions: Drown conditions: Drowning; Anoxia conditions: Drowning, Near conditions: Drowning and Nonfatal Submersion conditions: Drowning or Immersion of Unknown Intent conditions: Drowning and Submersion, Undetermined Intent conditions: Drowning and Submersion While in Natural Water conditions: Drowning and Submersion Due to Sailboat Sinking conditions: Drowning and Submersion Due to Fall Off Ship studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 120 type: ESTIMATED name: Drowning incident measure: Annual incidence of drowning treated by the Danish SAR helicopters from 2014-2023 measure: Annual incidence rate of drowning treated by the Danish SAR helicopters from 2014-2023 measure: Spatial distribution of drowning patients treated by the Danish SAR helicopters from 2014-2023 measure: Drowning to water rescue ratio sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Prehospital Center city: Næstved state: Region Zealand zip: 4700 country: Denmark lat: 55.22992 lon: 11.76092 hasResults: False
nctId: NCT06322121 id: NL83653.058.23 briefTitle: Vascular Aspects in Dementia: Part 2 overallStatus: RECRUITING date: 2023-09-04 date: 2026-09 date: 2026-09 date: 2024-03-20 date: 2024-04-11 name: Leiden University Medical Center class: OTHER briefSummary: Cerebral amyloid angiopathy (CAA), a common cerebrovascular small vessel disease (SVD), is a frequently (98%) found co-morbidity at autopsy in patients with Alzheimer's disease (AD). Current in vivo hallmarks of CAA represent changes relatively late in the disease process and leaves CAA in AD often undetected. Recently, it was shown that decreased vascular reactivity (VR) measured with blood oxygen level dependent (BOLD) MRI, after visual stimulus, is an early CAA marker. With BOLD-MRI to detect decreased VR in different stages of AD, it was shown that increasing stages of AD associate with decreasing VR independent of age, classic SVD markers and atrophy. Moreover, VR is associated with cognitive deficits. Therefore, cross-sectional data indicate that decreased VR is an important co-morbidity already in early stages of AD with an independent effect on disease severity. In this respect, the study aim is to determine the natural course of the decrease of VR in both controls and (early stage) AD patients to monitor AD disease progression. This is an essential step to aid in the development and application of effective treatment as it is expected that CAA can cause/worsen AD pathology. conditions: Dementia studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 120 type: ESTIMATED name: MRI measure: Vascular reactivity - BOLD amplitude measure: Vascular reactivity - time-to-peak measure: Vascular reactivity - time-to-baseline measure: Intracranial hemorrhage measure: Lobar microbleeds measure: Subarachnoidal hemorrhage measure: Superficial siderosis measure: Lacunes measure: Volume of white matter hyperintensities (WMHs) measure: Perivascular spaces in the basal ganglia measure: Perivascular spaces in the centrum semiovale measure: Gray matter volume sex: ALL minimumAge: 50 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Leids Universitair Medisch Centrum status: RECRUITING city: Leiden zip: 2333 ZA country: Netherlands name: Suzanne E van Dijk, drs role: CONTACT email: S.E.van_Dijk.RADI@lumc.nl lat: 52.15833 lon: 4.49306 hasResults: False
nctId: NCT06322108 id: IMMONC0008 briefTitle: Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008) overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2030-04 date: 2030-04 date: 2024-03-20 date: 2024-03-20 name: Immune Oncology Research Institute class: OTHER name: Agenus Inc. briefSummary: The goal of this study is to see if the combination of immunotherapy agents botensilimab and balstilimab is safe and effective in participants with metastatic non-small cell lung cancer (NSCLC) as a first-line treatment. conditions: Non-small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 45 type: ESTIMATED name: Botensilimab + Balstilimab measure: 12-Month Progression-Free Survival (PFS) measure: Objective Response Rate (ORR) measure: Disease Control Rate (DCR) measure: Duration of Response (DOR) measure: Time to Next Treatment (TTNT) measure: Overall Survival (OS) Time measure: Frequency, severity, and duration of treatment emergent adverse events (TEAEs) (Safety and tolerability) measure: Health-related quality of life (HRQoL) according to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) measure: Health-related quality of life according to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC29) measure: Health-related quality of life according to the 5 Level EuroQol 5 Dimension (EQ-5D-5L) questionnaire measure: Correlation between baseline expression of PD-L1 by immunohistochemistry (IHC) and 12-month progression-free survival measure: Correlation between baseline expression of PD-L1 by immunohistochemistry (IHC) and objective response rate measure: Correlation between existence of liver metastases on imaging at baseline and 12-month progression-free survival measure: Correlation between existence of liver metastases on imaging at baseline and objective response rate measure: Level of circulating tumor DNA (ctDNA) at baseline and at different time points after start of treatment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hematology Center named after prof. R. Yeolyan city: Yerevan zip: 0014 country: Armenia name: Samvel Bardakhchyan, MD, PhD role: CONTACT phone: +374 (010) 283800 email: samvelbardakhchyan@gmail.com name: Amalya Sargsyan, MD role: CONTACT phone: +374 (010) 283800 email: amalyasargsyan@gmail.com lat: 40.18111 lon: 44.51361 hasResults: False
nctId: NCT06322095 id: GH21C202 briefTitle: A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors overallStatus: NOT_YET_RECRUITING date: 2024-03-22 date: 2025-09-30 date: 2025-12-31 date: 2024-03-20 date: 2024-03-20 name: Suzhou Genhouse Bio Co., Ltd. class: OTHER briefSummary: This study is aim to evaluate the preliminary efficacy of GH21 combined with previous target therapy or immunotherapy in patients with advanced solid tumors. conditions: Patient With Advanced Solid Tumor studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 72 type: ESTIMATED name: GH21+ Previous Target Therapy or Immunotherapy measure: Objective response rate (ORR) measure: Number of participants with adverse events measure: Duration of response (DOR) measure: Duration of response (DCR) measure: Progression-free survival (PFS) measure: Plasma concentration (Cmax) measure: Time to achieve Cmax (Tmax) measure: Area under the plasma concentration-time curve (AUC) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cancer Hospital Chinese Academy of Medical Science city: Beijing state: Beijing zip: 100029 country: China name: Ning Li, Doctorate role: CONTACT phone: +86-10-87788495 email: lining@cicams.ac.cn lat: 39.9075 lon: 116.39723 hasResults: False